Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

Phase 2 Completed 32 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Genentech, Inc. · collab Hoffmann-La Roche · collab Massachusetts General Hospital · collab OSI Pharmaceuticals · collab Sanofi-Synthelabo · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is designed to investigate the safety, tolerability and the effectiveness when OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer.

Timeline

Start: 2003-03
Primary completion: 2006-08
Completion: 2006-08

Publications

Results Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006 Apr 20;24(12):1892-7. doi: 10.1200/JCO.2005.05.3728.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	750 mg/m2	Oral
Subject	Capecitabine	Small molecule	1000 mg/m2	Oral
Subject	Erlotinib	Small molecule	150 mg	Oral
Subject	Oxaliplatin	Small molecule	130 mg/m2	Intravenous

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

Summary

Timeline

Publications

Drugs

Indications